Gilead Sciences Inc. (NASDAQ: GILD) has agreed to acquire Ouro Medicines for 1.675 billion dollars in upfront cash, plus up to 500 million dollars in…
March 23, 2026
Pfizer Is Pushing Forward on a Lyme Disease Vaccine — Even After Missing Its Trial Goal
Pfizer (NYSE: PFE) and French biotech partner Valneva (Nasdaq: VALN) are moving toward regulatory submissions for their Lyme disease vaccine candidate, a decision that’s as…
Shares of Mobix Labs, Inc. (NASDAQ: MOBX) are pushing higher again today, recently up around 27% as momentum traders continue to ride the stock’s defense‑driven rebound. The move…
Structure Therapeutics Inc. (NASDAQ: GPCR) just delivered some of the strongest weight‑loss data yet for an oral GLP‑1, instantly elevating its M&A appeal in the…
The FDA has, for the first time, cleared a specific kind of cell therapy for human testing in epilepsy, backing an allogeneic GABA‑producing cell therapy…
March 16, 2026
Magdalena Biosciences, the Jaguar Health–Filament Health JV, has begun preclinical tests of coca-based appetite suppressants.
Magdalena Biosciences, a joint venture between Jaguar Health, Inc. (NASDAQ: JAGX) and Filament Health Corp. (OTC: FLHLF), has initiated a preclinical study evaluating whole-leaf coca…
Shares of The Beachbody Company, Inc. (ticker: BODI) are jumping today, up about 32% to $11.00 after opening at $9.995 and trading between $9.78 and $11.50 so far in the session. The spike comes on volume…
Redwire Corporation (NYSE: RDW) has secured an additional $4 million in funding from NASA to accelerate space-based drug development using its Pharmaceutical In‑space Laboratory (PIL‑BOX) platform…
The global chronic kidney disease (CKD) market is expected to expand steadily over the next decade as rising disease prevalence, earlier diagnosis, and continued pharmaceutical…
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) has expanded its rare disease portfolio through the acquisition of U.S. commercialization rights to HEMANGEOL®, the only FDA-approved oral treatment…
Silo Pharma, Inc. (NASDAQ: SILO) shares moved sharply higher after the company announced a $1 million share repurchase program, signaling management’s confidence in the company’s…
February 23, 2026
Bora Pharmaceuticals Secures $250 Million Manufacturing Deal with GSK, Expanding Long-Term Revenue Visibility
Bora Pharmaceuticals Co., Ltd. (OTCQX: BORAY) has signed a five-year global manufacturing agreement valued at approximately $250 million with GSK plc (NYSE: GSK), strengthening its…